Spin-off company of the Masaryk University
Institute of Biostatistics and Analyses (IBA) is a spin-off company of the Masaryk University, with a share of ownership by the Masaryk University.
The company focuses mainly on the areas of project management of clinical research, real-world evidence (RWE) projects, organisation and management of clinical trials, particularly non-interventional clinical trials and health registries. This main activity is complemented with other services such as market access support, cost-effectiveness analysis, pharmacovigilance, analysis of clinical data, development of tailored software products and graphic design.
About us
We are proud to announce that we have reached a significant milestone by receiving certification from the European Clinical Research Infrastructure Network (ECRIN), making IBA the 22nd certified data center within the network.
On 30 April 2024, the Institute of Biostatistics and Analyses s.r.o. (IBA) - Spin-off company of the Masaryk University - celebrated its tenth anniversary in the field of clinical data management and data science.
We are very pleased to have won a fantastic second place in the Company of the Year: Equal Opportunities 2024 competition. Our commitment to equal opportunities and work-life balance has paid off and we have been recognized among many great companies.
Quality management
Pharmacovigilance
Web studio
Real-world evidence/data
The Institute of Biostatistics and Analyses is an investigator of the project “Extending services portfolio of an information system for the data management in clinical research”. The project is supported by the OP EIC from the European Union funds.
Main objective of the project is the development of a platform for composition of information systems focused on data management and data mining in the field of pharmaceutical industry and life sciences. Offer of digital services based on a developed and validated information system will make reliable analytical models accessible to the companies for their decision-making and precise information sources for regulatory bodies. The project steps out of a laboratory environment of clinical trials and focuses on the evidence supported by real-world data.
